Saturday, July 28, 2018

2:20 PM - 3:00 PM

Maritime Room 1

Sponsored By: AbbVie

---

Details

At the end of 2016, 199,412 Australians were believed to be living with chronic hepatitis C. Previously, only 1.3% of people living with hepatitis C received treatment, and, left untreated, chronic hepatitis C can lead to liver failure, liver cancer and death. Significant advances in treatment and improvement to medication access has meant pharmacists play an increasingly important role in disease management in this area. Learning Objectives: • List common risk factors for hepatitis C transmission. • Outline the mechanism of action, contraindications and potential side effects of hepatitis C direct-acting antivirals (DAAs). • Identify suitable treatment regimens for people with hepatitis C based on their genotype, cirrhotic status and prior treatment experience. • Discuss a pharmacist’s role in the provision of treatment and advice to clients with hepatitis C Competencies (2010): 4.3.1, 4.3.2, 4.2.1, 4.2.3 Competencies (2016): 3.1.1, 3.2.2, 3.2.3

---

Speaker